

Recombinant Mouse c-MET/HGFR Protein (His Tag)

Catalog Number: PKSM040580

Note: Centrifuge before opening to ensure complete recovery of vial contents.


Description

Species	Mouse
Source	HEK293 Cells-derived Mouse c-MET/HGFR protein Met 1-Asn 929, with an C-terminal His
Calculated MW	102 kDa
Observed MW	41.8&87.2 kDa
Accession	EDL13881.1
Bio-activity	Immobilized HGF Protein, Mouse, Recombinant at 2ug/mL (100 uLwell) can bind c-MET Protein, Mouse, Recombinant (ECD,His Tag), the EC ₅₀ is 80-400 ng/mL.

Properties

Purity	> 90 % as determined by reducing SDS-PAGE.
Endotoxin	< 1.0 EU per µg of the protein as determined by the LAL method.
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80 °C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.
Formulation	Lyophilized from sterile PBS, pH 7.4 Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual.
Reconstitution	Please refer to the printed manual for detailed information.

Data



> 90 % as determined by reducing SDS-PAGE.

Background

For Research Use Only

Hepatocyte growth factor receptor (HGFR), also known as c-Met or mesenchymal-epithelial transition factor (MET), is a receptor tyrosine kinase (RTK) that has been shown to be overexpressed and/or mutated in a variety of malignancies. HGFR protein is produced as a single-chain precursor, and HGF is the only known ligand. Normal HGF/HGFR signaling is essential for embryonic development, tissue repair or wound healing, whereas aberrantly active HGFR has been strongly implicated in tumorigenesis, particularly in the development of invasive and metastatic phenotypes. HGFR protein is a multifaceted regulator of growth, motility, and invasion, and is normally expressed by cells of epithelial origin. Preclinical studies suggest that targeting aberrant HGFR signaling could be an attractive therapy in cancer.